AJG vs NU

AJG's deterministic health score is weak, with a Piotroski F-Score of 4/9 indicating marginal financial stability and no available Altman Z-Score to confirm safety from distress. Despite strong revenue growth of 20% YoY, earnings are sharply declining (-25.2% YoY, -54% EPS), and the stock trades at a steep valuation (P/E 40.0, Forward P/E 19.06) well above sector averages. Insider selling is aggressive ($17.16M in net sales), and recent earnings misses have become frequent, with 3 out of the last 4 quarters missing estimates. While the balance sheet shows moderate leverage (Debt/Equity 0.59), weak profitability trends, deteriorating earnings momentum, and bearish technicals point to significant near-term risks.

NU presents a stark contrast between traditional accounting health and explosive growth metrics, highlighted by a weak Piotroski F-Score of 2/9. While the deterministic health score is poor, the company's operational performance is exceptional, featuring 60.9% YoY earnings growth and a highly attractive PEG ratio of 0.85. The current price of $14.48 trades at a significant premium to the Graham Number ($5.51) but remains below the growth-based intrinsic value of $17.11. Ultimately, the strong ROE of 30.28% and aggressive scaling suggest a high-growth fintech trajectory that outweighs short-term deterministic health warnings.